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Abstract: Retinal diseases are the leading causes of irreversible blindness worldwide. The role of
toll-like receptor (TLR) signalling mechanisms (MyD88 and TRIF) in the production of pro-angiogenic
growth factors from human microvascular endothelial cells (HMEC-1) under hypoxic stress remains
unexplored. HMEC-1 was incubated under normoxic (5% CO2 at 37 ◦C) and hypoxic (1% O2,
5% CO2, and 94% N2; at 37 ◦C) conditions for 2, 6, 24, and 48 h, respectively. For TLR pathway
analysis, HMEC-1 was pre-treated with pharmacological inhibitors (Pepinh-MyD88 and Pepinh-
TRIF) and subjected to normoxia and hypoxia conditions. Gene and protein expressions of vascular
endothelial growth factor-A (VEGF-A), fibroblast growth factor (FGF-2), hypoxia inducible factor
1-alpha (HIF1-α) were performed using quantitative polymerase chain reaction (qPCR), ELISA, and
Western blot methodologies. Levels of TLR3 and TLR4 were analysed by flow cytometry. Under
hypoxia, levels of VEGF-A and FGF-2 were elevated in a time-dependent fashion. Inhibition of
MyD88 and TRIF signalling pathways decreased FGF-2 levels but failed to modulate the secretion of
VEGF-A from HMEC-1. Blocking a known regulator, endothelin receptor (ETR), also had no effect on
VEGF-A secretion from HMEC-1. Overall, this study provides the proof-of-concept to target TLR
signalling pathways for the management of blinding retinal diseases.
Keywords: retinal diseases; blindness; toll-like receptor; vascular endothelial cells; angiogenesis;
VEGF; FGF; ischemia; hypoxia
1. Introduction
Vision is paramount for healthy ageing, and its impairment or loss is considered a
major disability. Retinal diseases such as age-related macular degeneration (AMD) and
diabetic retinopathy (DR), including diabetic macular oedema (DMO), are the leading
causes of irreversible blindness worldwide [1]. AMD is a progressive neurodegenerative
disease of the retina, which is clinically sub-divided into two forms: dry (geographic
atrophy—GA) and wet (neovascular—nAMD). It is highly prevalent in individuals above
60 years of age and accounts for approximately 8.7% of all blindness [2]. DR, with DMO or
proliferative DR (PDR), is highly prevalent in the working-age population and commonly
affects individuals that are suffering from long-standing diabetes mellitus [1]. DMO,
PDR, and nAMD are characterised by increased vascular permeability resulting in macular
oedema and/or neovascularisation, with haemorrhage in retinal and vitreous space, fibrotic
scarring, and traction retinal detachment. Inflammation and hypoxia/ischaemia are the
two main pathophysiological determinants of retinal and choroidal vascular abnormalities
that are associated with these diseases [1].
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Hypoxia is a condition in which oxygen tension is adequately deficient at tissue level,
this then upregulates cellular expression of hypoxia-inducible factor-1α (HIF1-α) [3]. HIF1-
α regulates the synthesis and release of angiogenic factors such as fibroblast growth factor
(FGF-2) and VEGF-A [4]. Hypoxia-activated endothelin-1/endothelin receptor signalling
has been implicated in VEGF-A production from macrovascular endothelial cells and
melanoma cells [5]. Moreover, increased plasma levels of endothelin-1 have been associated
with the risk of nAMD [6]. Thus far, the underlying mechanisms of pathophysiology of
hypoxia-mediated microvascular angiogenesis/proliferation and resultant fibrotic scarring
remain elusive.
Toll-like receptors (TLRs) are a distinct family of transmembrane pattern-recognition
receptors that are expressed on a variety of ocular tissues and cells and have been associ-
ated with a number of vascular and inflammatory diseases [7–9]. TLR3 has been shown
to be present on RPE, retinal and choroidal endothelial cells [7,10]. Ligand activation of
TLR3 in RPE cells increases Toll/interleukin-1 receptor (TIR) domain-containing adaptor
protein-inducing interferon-β (TRIF) dependent secretion of VEGF and reduction in RPE
viability [11]. Mouse models deficient in TLR3 showed augmented laser-induced neovas-
cularization [12,13], while loss-of-function polymorphism of TLR3 gene in humans has
been reported to be protective against dry AMD [14,15]. Thus far, the role of TLR3 on
vascular endothelial cells during hypoxic stress remains unexplored. TLR4 mediates its
downstream signalling through both myeloid differentiation factor 88 (MyD88), as well
as TRIF-dependent signalling pathways [16]. Our laboratory was first to demonstrate
the expression of TLR4 on primary retinal and choroidal vascular endothelial cells [7].
Previous studies have implicated the role of TLR4 in retinal damage caused by ischaemia
and PDR [17,18]. In addition, TLR4 was shown to participate in phagocytosis of photore-
ceptor outer segments by the RPE [19,20]. These findings suggest that TLR4 on RPE and
photoreceptors cells has a crucial role in retinal ischaemic injury. However, the role of TLR4
on microvascular endothelium during ischaemic injury is still not clearly understood.
In this study, we aimed to establish the role of MyD88 and TRIF signalling pathways
on production of VEGF-A and FGF-2 from the human microvascular endothelial cells,
as a model for retinal microvascular endothelium, during normoxia and hypoxia. We
have also validated the role of ETR in regulation of VEGF-A in HMEC-1 during hypoxia.
As there may be significant exposure of donor eyes to post-mortem hypoxia preceding
isolation of human retinal and choroidal endothelial cells (hREC and hCEC), and in order
to allow for such potential variability in hypoxia exposure in the primary isolated hCEC,
human microvascular EC lines (HMEC-1) were used for a significant part of this study
after establishing their TLR expression as similar to that of hREC and hCEC. This study
extends our previous reports on the signalling mechanisms in microvascular angiogen-
esis, and their relevance in intraocular, particularly retinal and choroidal ischaemia and
neovascularisation. Here, we demonstrated that hypoxia-activated signalling pathways in
HMEC-1 are regulated through TLRs.
2. Materials and Methods
The research was complied with the institutional regulations of good laboratory
practice (GLP) and Health and Safety guidelines of the University of Nottingham. Aseptic
conditions were followed in all experiments, which were performed within the laminar
flow air hood (Envair, Rossendale, UK).
2.1. Cell Culture
Simian virus (SV-40) immortalised human microvascular endothelial cell line (HMEC-
1) was commercially obtained (ATCC-LGC Standards, Teddington, Middlesex, UK). In this
study, cellular passages 7 to 15 were utilised. HMEC-1 was cultured in the growth media
recommended by ATCC (MCDB131 basal medium (ThermoFisher Scientific, Waltham, MA,
USA) supplemented with 10% fetal bovine serum (FBS), 10 mM L-glutamine, 10 ng/mL
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epidermal growth factor (EGF), 1 µg/mL Hydrocortisone and antibiotic-antimitotic mixture
(gentamicin and amphotericin B; Sigma-Aldrich, Gillingham, UK).
2.2. Normoxia and Hypoxia Treatment
HMEC-1 was seeded on appropriate culture plates and incubated at 37 ◦C, 5% CO2
(Sanyo Electric Co Ltd., Osaka, Japan) until 80% confluency. Before treatment, HMEC-1
was starved overnight in MCDB131 basal medium without growth factors. For hypoxic
treatment, cells were exposed to 1% O2, 5% CO2, and 94% N2 within a tightly sealed
hypoxia chamber InvivO2 400 (I&L Biosystems UK Ltd., Chertsey, Surrey, UK) for different
durations (2, 6, 24 and 48 h, respectively). HMEC-1 incubated at normoxic conditions
(37 ◦C and 5% CO2) was used as normoxia controls.
2.3. Inhibition of Key Signal Transduction Pathways
To assess the role of key signalling pathways in regulation of VEGF-A and FGF-2, we
have used following pharmacological inhibitors: Pepinh-MyD88 (5, 10, 20 and 40 µM),
Pepinh-TRIF (5, 10, 20 and 30 µM) and Pepinh-Control (20, 30 and 40 µM) (Invivogen, San
Diego, CA, USA). In addition, a protein synthesis inhibitor, Cycloheximide (25 µg/mL,
50 µg/mL, 100 µg/mL) (Cell Signalling, London, UK) and an endothelin receptor agonist,
BQ-123 (1 µM, 5 µM, 10µM) (Bio-Techne Ltd., Abingdon, UK), were also used to assess
their effect on VEGF and FGF-2 secretion from HMEC-1.
2.4. Cell Viability Assay
HMEC-1 viability was determined using cell counting kit-8 (CCK-8) (Sigma-Aldrich,
Gillingham, UK). Then, 1.5 × 104 cells were seeded into each well of four individual
96-well plates and incubated at 37 ◦C, 5% CO2. Following overnight starvation, plates were
incubated under normoxic and hypoxic conditions for different durations. At the end of
each incubation, 10 µL CCK-8 was applied into each well and further incubated for 2 h.
Viable cells converted the WST-8 dye into formazan, which was measured at optical density
450 nm using the CLARIOstar Microplate-reader (BMG LABTECH, Ortenberg, Germany).
2.5. Total RNA Isolation
Total RNA was extracted according to manufacturer’s protocol (RNeasy mini kit;
Qiagen, Manchester, UK). Following treatment, HMEC-1 was lysed with 650 µL RLT
lysis buffer (Qiagen, Manchester, UK) and homogenised using QIAshredder column. The
lysate was then mixed with equal volume of 70% ethanol. The mixture was applied into
new nucleic acid binding-column and centrifuged at 10,000× g for 15 s. The filtrate was
discarded, and spin columns were washed with buffers RW1 and RPE (Qiagen, Manchester,
UK), respectively, by centrifugation. Total RNA was eluted in RNase-free water and
quantified using CLARIOstar Microplate-reader (BMG LABTECH, Ortenberg, Germany).
2.6. Reverse Transcription into Complementary DNA (cDNA)
Using a commercial kit (Quantitect Reverse Transcription kit; Qiagen, Manchester,
UK), total RNA (1 µg) was reverse transcribed into cDNA. Total RNA was mixed with
genomic DNA wipeout buffer (Qiagen, Manchester, UK) and incubated at 42 ◦C for 2 min.
The mix was placed on ice, and then buffered reverse transcriptase (Quantitect Reverse
Transcriptase, RT Buffer, and RT Primer mix; Qiagen, Manchester, UK) was added. The
final mix was incubated for 30 min at 42 ◦C for cDNA synthesis. This was followed by a
reverse transcriptase deactivation step for 3 min at 95 ◦C. cDNA samples were then stored
at −20 ◦C until further analysis.
2.7. Quantitative Polymerase Chain Reaction (qPCR)
QPCR analysis of the desired gene of interest was performed using inventoried Taq-
Man probe chemistry (Table 1) (ThermoFisher Scientific, Waltham, MA, USA) as previously
described [21]. The qPCR reactions were run in an 8-strip optical tubes (Starlab (UK) Ltd.,
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Milton Keynes, UK) using Taqman gene expression mastermix in the Mx3005p real-time
PCR instrument (Agilent Technologies, Cheshire, UK) as detailed in the manufacturers
protocol (ThermoFisher Scientific, Waltham, MA, USA). Briefly, template cDNA was di-
luted 1 in 5 with nuclease-free water to perform qPCR in duplicate. Each reaction was
prepared to 20 µL final reaction volume containing 15 µL of PCR reaction mix and 5 µL of
diluted cDNA template. Each 8-strip tube was run with a Taqman probe/primer mix for
the gene of interest and endogenous controls (Table 1). Appropriate negative non-template
controls were also run. Samples were loaded and run under appropriately set experimental
settings and PCR thermal cycling conditions recommended by the manufacturer. Data
were acquired on the MxPro Software (version 4.01, Stratagene, Cambridge, UK) and trans-
ferred to a Microsoft Excel spreadsheet for analysis using the delta-delta CT comparative
quantitation method.
Table 1. TaqMan probes utilised for qPCR analysis.
Gene Name Assay ID Gene Symbol
Vascular Endothelial Growth Factor A Hs00900055_m1 VEGFA
Fibroblast Growth Factor 2 Hs00266645_m1 FGF2
Hypoxia Inducible Factor 1 alpha Hs00153153_m1 HIF1A
Toll Like Receptor 3 Hs01551079_g1 TLR3
Toll Like Receptor 4 Hs00152939_m1 TLR4
Hypoxanthine phosphoribosyl transferase 1 Hs99999909_m1 HPRT1
2.8. Flow Cytometry
Flow cytometry was performed to analyse the intracellular and extracellular expres-
sion of TLR3 and TLR4 in response to normoxia and hypoxia. Following treatment,
HMEC-1 was collected using 1× TrypLE buffer (Life Technologies Ltd., Paisley, UK) by
centrifugation. For intracellular antigens, HMEC-1 was fixed in Cytofix/Cytoperm solu-
tion (BD Biosciences, Wokingham, UK) for 30 min at 4 ◦C, permeabilised with Perm Wash
(BD Biosciences, Wokingham, UK) and blocked with 10% heat inactivated normal human
serum (HINHS) for 30 min at 4 ◦C. For extracellular antigens, HMEC-1 was suspended
in FACS Buffer, centrifuged, and blocked with 10% HINHS for 30 min at 4 ◦C. Staining
was performed using PE-conjugated monoclonal anti-human antibodies: TLR3 (CD283;
clone TLR3.7; RRID:AB_466235), TLR4 (CD284; clone HTA125; RRID:AB_2537727), and
TLR9 (CD289; clone eB72-1665; RRID:AB_466238) (eBioscience, Hatfield, UK) in dark for
1 h at 4 ◦C. Unstained samples and samples stained with isotype-specific controls (Mouse
IgG1 κ Isotype Control, and Mouse IgG2a κ Isotype Control; eBioscience, Hatfield, UK)
served as negative controls. Immediately following staining, cells were fixed in 500 µL of
2% paraformaldehyde (PFA) for 15 min at 4 ◦C, washed in FACS buffer and re-suspended
in 1x PBS for data acquisition on BD-LSRII Flow Cytometer. The data collected using FACS
Diva software (Ver 6.0) and analysed using Kaluza data analysis software (Ver 2.0).
2.9. ELISA
The concentrations of VEGF-A and FGF-2 protein in the conditioned culture media
was determined using ELISA as previously described [22]. Human VEGF-A and FGF2
DuoSet ELISA kits were supplied by R&D Systems (Minneapolis, MN, USA). ELISA plates
were coated overnight with the working concentrations of capture antibody (VEGF-A:
1 µg/mL or FGF-2: 2 µg/mL) at room temperature. Plates were washed six times with
Wash Buffer, blocked with Reagent Diluent (1% BSA in 1× PBS) and incubated for 1 h
at room temperature. Washing steps were repeated and culture media was centrifuged
at 1000 g for 5 min. Recombinant standards (at different concentrations) and samples
(1 in 2 diluted) were incubated for 2 h at room temperature. ELISA plates washed and
incubated with working concentrations of detection antibody (Biotin conjugated anti-
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human VEGF-A: 100 ng/mL) or (Biotic conjugated anti-human FGF2: 250 ng/mL) for 2 h
at room temperature. After washing step, 100 µL of working dilution of streptavidin-HRP
(40-fold dilution) was added to each well and incubated for 20 min in the dark. The plates
were washed, and 100 µL of substrate solution (1:1 mixture of Colour Reagent A and B)
was added to each well and incubated at room temperature for 20 min in the dark. The
colour development was stopped using 50 µL of stop solution, and optical density was
determined using CLARIOstar Microplate-reader (BMG LABTECH, Ortenberg, Germany)
at 450 nm and corrected with 540 nm. The data were analysed by 4-parameter linear
regression method.
2.10. Protein Estimation for Immunoblotting
Total protein was extracted from treated HMEC-1 using Urea lysis buffer containing
5% V/V glycerol, 10 mM Tris (pH 6.8), 0.05% W/V sodium dodecylsulfate (SDS) and
1 mM β-mercaptoethanol. The lysate was collected by centrifugation at 1000 g for 5 min at
4 ◦C. Protein concentrations were then determined with BCA Protein Assay Kit (Pierce;
ThermoFisher Scientific, Waltham, MA, USA) according to manufacturer’s instructions
at 562 nm optical density using CLARIOstar Microplate-reader (BMG LABTECH, Orten-
berg, Germany).
2.11. Western Blot
Western blotting was performed as previously described [23]. Protein extracts were
mixed with 4× SDS sample buffer and incubated for 3 min at 95 ◦C. Protein samples (100 µg)
were separated using precast 4–12% NuPAGE gel and blotted onto a PVDF membrane.
The membranes were then blocked with 5% W/V non-fat dry milk in 1× TBST (0.05 M
tris-buffered saline (TBS) (pH 8.0) with 0.05% V/V Tween-20) and incubated with primary
antibodies overnight at 4 ◦C: Rabbit anti-human β-Actin polyclonal antibody (pAb). (1:1000;
Cat#4967; RRID:AB_330288; Cell Signalling, London, UK), Mouse anti-human HIF-1a mon-
oclonal antibody (1:500; Clone 241809; Cat#MAB1536 RRID:AB_2116983; R&D Systems,
Minneapolis, MN, USA) and Rabbit anti-human HIF-1α pAb (1:1000; Cat#NB100-479;
RRID:AB_10000633; Novus Biologicals, Littleton, CO, USA). Membranes were washed
and incubated with secondary antibodies at room temperature for 1 h (Anti-Rabbit IgG
AP-Linked Ab. (1:1000; Cat#7054; RRID:AB_2099235; Cell Signalling, London, UK) and
Anti-Mouse IgG AP-Linked Ab (1:1000; Cat#7056; RRID:AB_330921; Cell Signalling, Lon-
don, UK). The stained membranes were then incubated with 6 mL of BCIP/NBT Purple
Liquid Substrate (Sigma-Aldrich, Gillingham, UK) for 5 to 10 min in the dark. Developed
membranes were briefly washed with dH2O and digitally scanned.
2.12. Data Analysis
Data were expressed as mean ± standard deviation (SD) of three biological replicates
from each of two independent experiments. Statistical analysis of data was achieved
using statistical software, GraphPad Prism version 7.0 (GraphPad Software Inc., San
Diego, CA, USA). Alpha was set at p = 0.05, and different groups were analysed using
two-way ANOVA.
3. Results
3.1. Effect of Hypoxia on HMEC-1 Viability
As a first step, we assessed the effect of hypoxia on viability of HMEC-1 for differ-
ent durations (24 and 48 h). As shown in Figure 1, no significant decrease in HMEC-1
viability was detected at 24 h under hypoxia. However, a 54% reduction in cell viability
(p ≤ 0.0001) was observed following 48 h of hypoxic stress compared to cells incubated in
normoxic conditions.
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Figure 1. Viability of HMEC-1 in normoxic and hypoxic conditions. HMEC-1 was treated under 
normoxia and hypoxia conditions for 24 h and 48 h, respectively. Cell viability was assessed using 
CCK-8 kit. Results were presented as percentage (%) viability, and all data were quantified from 
two biological replicates from n = 3 independent experiments. 
3.2. Hypoxia Treatment Modulates mRNA Expression of Growth Factors, HIF1-α, and Toll-Like 
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We aimed to assess the longitudinal effect of hypoxic stress on mRNA expression of 
VEGF-A, FGF2, HIF1-α, TLR3 and TLR4 in HMEC-1. Under hypoxia (Figure 2A), VEGF-A 
mRNA was elevated to 5.8  1.45 folds at 6 h (p  0.0001) and 12.2  4.27 folds at 24 h (p  
0.0001). At 48 h, VEGF-A mRNA was moderately declined (6.4  1.3 folds; p  0.0001) but 
remained at high levels similar to that at the 6 h time-point. FGF-2 (Figure 2B), on the other 
hand, was elevated up to 2.4  1-fold at 24 h (p = 0.0017) and remained unchanged until 
48 h (p = 0.0061) of hypoxia. HIF1-α (Figure 2C) showed reduced expression until 6-h hy-
poxic stress compared to normoxia. However, after 24 h of hypoxic stress, HIF1-α mRNA 
was modestly elevated with significant increase noted at 48 h (1.60  0.15 folds; p = 0.0458). 
As shown in Figure 2D, TLR3 mRNA levels did not change significantly under hypoxia 
until 24 h. Notably, at 48 h, TLR3 mRNA was reduced by more than 90% (p = 0.0351) in 
hypoxic samples. In stark contrast, TLR4 mRNA (Figure 2E) was increased at 24 h (5.8  
0.53 folds) and sustained until 48 h of hypoxic stress (4.0  0.73 folds, p  0.001).  
Figure 1. Viability of HMEC-1 in normoxic and hypoxic conditions. HMEC-1 was treated under
normoxia and hypoxia c nditions for 24 h a d 48 h, respectively. Cell v ability was assessed using
CCK-8 kit. Results were presented as percentage (%) viability, and all data were quantified from two
biological replicates from n = 3 independent experiments.
3.2. Hypoxia Treatment Modulates mRNA Expressio of Growth Factors, HIF1-α, and
Toll-Like Receptors
We aimed to assess the longitudinal effect of hypoxic stress on mRNA expression of
VEGF-A, FGF2, HIF1-α, TLR3 and TLR4 in HMEC-1. Under hypoxia (Figure 2A), VEGF-A
mRNA was elevated to 5.8 ± 1.45 folds at 6 h (p ≤ 0.0001) and 12.2 ± 4.27 folds at 24 h
(p ≤ 0.0001). At 48 h, VEGF-A mRNA was moderately declined (6.4 ± 1.3 folds; p ≤ 0.0001)
but remained at high levels similar to that at the 6 h time-point. FGF-2 (Figure 2B), on the
other hand, was elevated up to 2.4 ± 1-fold at 24 h (p = 0.0017) and remained unchanged
until 48 h (p = 0.0061) of hyp xia. HIF -α (Figure 2C) showed reduced expression until 6-h
hypoxic stress compared to normoxia. However, after 24 h of hypoxic stress, HIF1-α mRNA
was modestly elevated with significant increase noted at 48 h (1.60 ± 0.15 folds; p = 0.0458).
As shown in Figure 2D, TLR3 mRNA levels did not change significantly under hypoxia
until 24 h. Notably, at 48 h, TLR3 mRNA was reduced by more than 90% (p = 0.0351)
in hypoxic samples. In stark contrast, TLR4 mRNA (Figure 2E) was increased at 24 h
(5.8 ± 0.53 folds) and sustained until 48 h of hypoxic stress (4.0 ± 0.73 folds, p ≤ 0.001).
3.3. Effect of Hypoxia on VEGF-A and FGF-2 Secretion from HMEC-1
Next, we quantitated the secretion of VEGF-A and FGF-2 protein from HMEC-1 under
hypoxia for different durations. As shown in Figure 3A, VEGF-A protein was not secreted
in normoxic conditions. Under hypoxia, a time-dependent increased secretion of VEGF-A
starting 6 h was noted. After 48 h f hypoxia challenge, VEGF-A protein was increased
and found to be 114 ± 43.25 pg/mL. Correspondingly, FGF-2 was released at normal
levels in supernatants of HMEC-1 under normoxic conditions (Figure 3B). Until 24 h of
hypoxia, FGF-2 was secreted at basal levels. Notably, at 48 h duration, the levels increased
significantly to 200 ± 89.86 pg/mL; p = 0.0008.
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Figure 2. Profile of mRNA expression of growth factors, toll-like receptors, cytokines and HIF1-α. HMEC-1 incubated in
normoxic and hypoxic conditions for different durations (2, 6, 24, and 48 h) was processed for gene expression analysis by
qPCR. VEGF-A (A), FGF-2 (B), HIF1-α (C), TLR-3 (D), and TLR-4 (E). All data repres ted as mean ± SD of six biological
replicates from two independent experiments.
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Figure 3. Hypoxic stress increases VEGF-A and FGF-2 secretion from HMEC-1 cells. Levels of 
VEGF-A (A) and FGF-2 (B) are measured in supernatants of HMEC-1 incubated under hypoxia and 
normoxia for different durations. All data represented as mean ± SD of six biological replicates from 
two independent experiments. 
3.4. Hypoxia Modulates Protein Expression of TLR3, TLR4 and HIF1-α in HMEC-1 
We examined the effect of hypoxic stress on intracellular levels of TLR3 and TLR4 at 
24 and 48 h time-points using flow cytometry. After 24 h under hypoxia, a mild increase 
in TLR3 levels was noted in HMEC-1 (Figure 4A). However, TLR4 levels remained un-
changed (Figure 4C). Notably, after 48 h of hypoxic stress, both TLR3 (Figure 4B) and 
TLR4 (Figure 4D) intracellular levels were elevated. We did not observe positive staining 
for TLR3 and TLR4 on extracellular surface of normoxic or hypoxic HMEC-1 (data not 
shown). As shown in Figure 5, signal intensity of HIF1-α was increased by 6 h (p = 0.0004) 
and remained elevated up to 24 h (p = 0.0096) of hypoxia. However, in normoxic HMEC-
1 lysates, we did not observe a positive protein band signal for HIF1-α. The loading con-
trol, -actin, was used to normalise the signal intensity. 
Figure 3. Hypoxic stress increases VEGF-A and FGF-2 secretion from HMEC-1 cells. Levels of
VEGF-A (A) and FGF-2 (B) are measured in supernatants of HMEC-1 incubated under hypoxia and
normoxia for different durations. All data represented as mean ± SD of six biological replicates from
two independent experiments.
3.4. Hypoxia Modulates Protein Expression of TLR3, TLR4 and HIF1-α in HMEC-1
We examined the effect of hypoxic stress on intracellular levels of TLR3 and TLR4
at 24 and 48 h time-points using flow cytometry. After 24 h under hypoxia, a mild in-
crease in TLR3 levels was noted in HMEC-1 (Figure 4A). However, TLR4 levels remained
unchanged (Figure 4C). Notably, after 48 h of hypoxic stress, both TLR3 (Figure 4B) and
TLR4 (Figure 4D) intracellular levels were elevated. We did not obs rve positive staining
for TLR3 and TLR4 on extracellular surface of normoxic or hypoxic HMEC-1 (data not
shown). As shown in Figure 5, signal intensity of HIF1-α was increased by 6 h (p = 0.0004)
and remained elevated up to 24 h (p = 0.0096) of hypoxia. However, in normoxic HMEC-1
lysates, we did not observe a positive protein band signal for HIF1-α. The loading c ntrol,
β-actin, was used to normalise the signal intensity.




Figure 4. Increased expression of TLR3 and TLR4 in HMEC-1 cells under hypoxia. Intracellular lev-
els of TLR3 (A,B) and TLR4 (C,D) in HMEC-1 under hypoxia and normoxia for 24 and 48 h, respec-
tively, was analysed by flow cytometry. Green: Isotype control Ab staining; blue: TLR Ab staining 
of normoxic cells; red: TLR Ab staining of hypoxic cells. Note: magenta colour was a result of over-
lapping histogram of normoxia (red) and hypoxia (blue). All data are representative of three inde-
pendent experiments. 
 
Figure 5. Accumulation of HIF1-α in HMEC-1 under hypoxia condition. (A) Monoclonal antibodies against human HIF1-
α and human -actin was utilised to determine the expression of HIF1-α and actin in HMEC-1 under hypoxia and 
normoxia for different durations. (B) The signal intensity was semi-quantitatively normalised against actin using ImageJ 
software (NIH). All data represented as mean ± SD of three independent experiments. The corresponding strips have been 
cropped in order to improve the clarity and conciseness of presentation. 
  
Figure 4. Increased expression of TLR3 and TLR4 in HMEC-1 cells under hypoxia. Intracellular
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3.5. TRIF Activation Pathway Plays a Key Role in Induction of VEGF-A and FGF-2
under Hypoxia
To study the role of TLR signalling pathways in regulation of VEGF-A and FGF-2
secretion under hypoxia, we pre-treated HMEC-1 with pharmacological inhibitor pep-
tides against MyD88 (Pepinh-MYD; 40 µM) and TRIF (Pepinh-TRIF; 30 µM) for 6 h
prior to hypoxic stress for 48 h. As shown in Figure 6A, MyD88 pathway inhibition
did not affect the VEGF-A levels under hypoxia. Blocking TRIF pathway significantly
reduced VEGF-A (up to 25%) compared to vehicle pre-treatment (29.83 ± 3.92 pg/mL;
p = 0.0104). Unlike VEGF-A, inhibition of MyD88 has markedly decreased FGF2 produc-
tion (90.0 ± 20.44 SD pg/mL; p = 0.0129) with levels matching basal FGF2 release from
normoxic HMEC-1 (Figure 6B). Similarly, inhibition of TRIF pathway prior to hypoxia also
reduced FGF2 levels significantly (90.1 ± 29.24 SD pg/mL; p = 0.0129).
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survival (or apoptosis) and/or proliferation in AMD. This study provides evidence that
hypoxia causes significant modulation of angiogenic growth factors (VEGF-A and FGF-2),
HIF-1α, and TLRs in microvascular endothelial cells.
A central role of the TLR-signalling in the regulation of innate immune response, as
well as a key regulator of hypoxia in angiogenesis, and the transcriptional effects of hypoxia
on TLRs have been previously described [31]. Significantly, Basu et al. described induction
of TLR4 and 2 in association with downstream signalling under hypoxia [32]. Recently,
TLR3 has been reported to be protective in arterial wall endothelium [33]. Similar protection
was demonstrated for synthetic TLR3 ligand (Poly I:C, especially in high doses) and thought
to be mediated through anti-inflammatory cytokine, IL-10 [33,34]. Furthermore, TLR3
deficiency is reported t promote EC apoptos s and increase expression of IL-6 and ET-1,
but not IL-10 [35], suggesting dysregulation of RNA expression or sensing resulting from
reduced expression. However, these previous investigations utilised macrovascular
endothelial cells, including arterial cells [33], stellate or Kupffer cells in the liver [34].
Both TLR3 and TLR4 have been implicated in DR [36] and retinopathy of prematurity
(ROP) [37] through stimulation of varying cytokines. Genetic mutations in TLR4 have also
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been implicated in DR development [38]. Ishida et al. reported that long-term hypoxia
reduced TLR stimulation of endothelial cells [39], whilst hypoxia exposure of macrophages
increased TLR4 expression [25]. Some reports have suggested that the early phase of
inflammatory response in ischaemia was mediated through MyD88 signalling, whilst the
TRIF signalling effect was important in the late phase [40].
We investigated MyD88 and TRIF explicitly, rather than each individual TLR, as these
adaptors together cover the signalling pathways of all TLRs. TLR3 utilises TRIF only,
whilst TLR4 signals through MyD88 and TRIF. Inhibition of the MyD88 pathway had
an insignificant effect on VEGF-A secretion in hypoxia, whilst there was only a minimal
reduction in VEGF-A secretion following TRIF signalling blockage. On the other hand,
inhibition of both TRIF and MyD88 signalling decreased FGF-2 production in HMEC-1,
confirming that FGF-2 induction is mediated through a different mechanism from VEGF-A.
Levels of HIF-1α in HMEC-1 under hypoxia were consistent with a previous report
that described HIF-1α-dependent regulation of FGF-2 in muscle cells under hypoxia [41].
Our findings have clearly demonstrated the redundant function of HIF-1α in HMEC-1
under hypoxia because blocking TLR signalling mechanisms (key regulators of HIF-1α
activity in hypoxic macrovascular ECs) inhibited FGF-2 but not VEGF-A production. This
warrants further characterisation or validation of HIF-1α function in microvascular ECs
under hypoxia. Recent reports have indicated the specific role of endothelin receptor (ETR)
in VEGF secretion from the macrovascular endothelial cells (HUVEC) and other cancer
cells under hypoxia [5,24]. Additionally, a relation between elevated serum ET-1 levels and
nAMD has been reported [6]. Unlike previous studies, our results demonstrated for the
first time that the ETR plays a redundant role in regulation of VEGF-A in HMEC-1. Instead,
FGF-2 was found to be regulated through ETR in HMEC-1.
The main limitation of this study is that it utilised HMEC-1 cells. However, the results
from this study are more applicable to retinal and choroidal vasculature, which consist of
microvascular endothelial cells similar to the HMEC-1 used in this study, unlike HUVEC.
Further studies with human REC and CEC are required for validation. Although hypoxia
has been shown to regulate TLR-mediated angiogenic growth factors, it is still unclear
how TLRs are activated under hypoxia. DAMPS have been shown to activate TLRs in a
variety of cell types [42]. A possibility is that hypoxia-triggered EC damage may release
DAMPS with subsequent TLR activation [43]. Further studies will elucidate this intriguing
phenomenon of feedback activation loop.
The findings from this study indicate that blockage of VEGF-A and FGF-2 pathways
may lead to complementary effects in the modulation and treatment of retinal ischaemic
diseases. This is underscored by the fact that, in clinical practice, a significant number of
eyes receiving anti-VEGF therapies for retinal vascular diseases (including nAMD, and
DR) show suboptimal response.
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